NasdaqCM - Nasdaq Real Time Price • USD
Pieris Pharmaceuticals, Inc. (PIRS)
As of 2:07 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | -- |
| Avg. Estimate | -0.12 | 0 | -0.35 | 0 |
| Low Estimate | -0.12 | 0 | -0.35 | 0 |
| High Estimate | -0.12 | 0 | -0.35 | 0 |
| Year Ago EPS | -8.8 | -14.4 | -36 | -0.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 1.3M | 2.24M | 42.81M | 6.62M |
| Low Estimate | 2.24M | 2.24M | 31.98M | 6.62M |
| High Estimate | 2.24M | 2.24M | 31.98M | 6.62M |
| Year Ago Sales | 5.85M | 6.5M | 25.9M | 42.81M |
| Sales Growth (year/est) | -77.80% | -65.50% | 65.30% | -84.50% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -18.4 | -11.2 | -12.8 | -8.8 |
| EPS Actual | -8.8 | -14.4 | 4 | 3.2 |
| Difference | 9.6 | -3.2 | 16.8 | 12 |
| Surprise % | 52.20% | -28.60% | 131.20% | 136.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.12 | 0 | -0.35 | 0 |
| 7 Days Ago | -0.12 | -0.06 | -0.35 | -0.2 |
| 30 Days Ago | -0.12 | -0.06 | -0.35 | -0.2 |
| 60 Days Ago | -0.12 | -0.06 | -0.35 | -0.2 |
| 90 Days Ago | -0.12 | -0.06 | -0.35 | -0.2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PIRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 98.60% | -- | -- | 1.50% |
| Next Qtr. | -- | -- | -- | 12.10% |
| Current Year | 99.00% | -- | -- | 4.40% |
| Next Year | -- | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Baird: Neutral to Outperform | 3/13/2020 |
| Downgrade | Baird: Outperform to Neutral | 7/30/2019 |
| Initiated | Baird: Outperform | 5/14/2019 |
| Initiated | Cowen & Co.: Outperform | 5/4/2018 |
| Initiated | Evercore ISI Group: Outperform | 3/19/2018 |
| Initiated | Jefferies: Buy | 3/19/2018 |
Related Tickers
BPTS Biophytis S.A.
8.22
0.00%
WINT Windtree Therapeutics, Inc.
5.43
+6.37%
LPTX Leap Therapeutics, Inc.
3.1700
0.00%
ATXI Avenue Therapeutics, Inc.
7.34
-16.36%
GRTX Galera Therapeutics, Inc.
0.2004
-3.42%
AFMD Affimed N.V.
4.8900
+0.20%
LVTX LAVA Therapeutics N.V.
2.7550
+4.36%
CDTX Cidara Therapeutics, Inc.
13.20
+1.54%
CTMX CytomX Therapeutics, Inc.
1.6000
0.00%
PHIO Phio Pharmaceuticals Corp.
0.6986
+3.80%